Bimekizumab is a recently approved injectable biologic agent for plaque psoriasis. In contrast to previous agents, it specifically targets the A/F subtypes of proinflammatory cytokine interleukin-17. While randomized clinical trials have been conducted for bimekizumab, these studies often do not reflect routine clinical practice due to limited follow-up and exclusion of certain patient populations (e.g. use of several prior biologics, comorbidities). Our study provides two-year real-world evidence of bimekizumab from four institutions in Canada, indicating an overall retention rate of 77.1% up to 2 years and affirming that bimekizumab is effective and safe for plaque psoriasis patients.